Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16715478,linear dynamic,The method exhibited a linear dynamic range of 0.1-100 ng/mL for perindopril in human plasma.,High-throughput quantification of perindopril in human plasma by liquid chromatography/tandem mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715478/),[ng] / [ml],0.1-100,5520,DB00790,Perindopril
,16715478,run time,A run time of 2.0 min for each sample made it possible to analyze more than 450 human plasma samples per day.,High-throughput quantification of perindopril in human plasma by liquid chromatography/tandem mass spectrometry: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715478/),min,2.0,5521,DB00790,Perindopril
,1576057,AUC,"Compared with a historical control group of young healthy volunteers receiving the same single oral dose of perindopril, mean AUC values of the prodrug perindopril were double in patients with liver cirrhosis (602 +/- 294 s.d. ng ml-1 h vs 266 +/- 70 s.d. ng ml-1 h) whereas the mean AUC of perindoprilat was found to be similar (134 +/- 139 ng ml-1 h vs 120 +/- 29 ng ml-1 h).",The pharmacokinetics of perindopril in patients with liver cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576057/),[h·ng] / [ml],602,8379,DB00790,Perindopril
,1576057,AUC,"Compared with a historical control group of young healthy volunteers receiving the same single oral dose of perindopril, mean AUC values of the prodrug perindopril were double in patients with liver cirrhosis (602 +/- 294 s.d. ng ml-1 h vs 266 +/- 70 s.d. ng ml-1 h) whereas the mean AUC of perindoprilat was found to be similar (134 +/- 139 ng ml-1 h vs 120 +/- 29 ng ml-1 h).",The pharmacokinetics of perindopril in patients with liver cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576057/),[h·ng] / [ml],266,8380,DB00790,Perindopril
,1576057,AUC,"Compared with a historical control group of young healthy volunteers receiving the same single oral dose of perindopril, mean AUC values of the prodrug perindopril were double in patients with liver cirrhosis (602 +/- 294 s.d. ng ml-1 h vs 266 +/- 70 s.d. ng ml-1 h) whereas the mean AUC of perindoprilat was found to be similar (134 +/- 139 ng ml-1 h vs 120 +/- 29 ng ml-1 h).",The pharmacokinetics of perindopril in patients with liver cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576057/),[h·ng] / [ml],134,8381,DB00790,Perindopril
,1576057,AUC,"Compared with a historical control group of young healthy volunteers receiving the same single oral dose of perindopril, mean AUC values of the prodrug perindopril were double in patients with liver cirrhosis (602 +/- 294 s.d. ng ml-1 h vs 266 +/- 70 s.d. ng ml-1 h) whereas the mean AUC of perindoprilat was found to be similar (134 +/- 139 ng ml-1 h vs 120 +/- 29 ng ml-1 h).",The pharmacokinetics of perindopril in patients with liver cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576057/),[h·ng] / [ml],120,8382,DB00790,Perindopril
,1576057,partial metabolic clearance,The partial metabolic clearance of perindopril to perindoprilat was much lower in the cirrhotics (26 +/- 12 ml min-1 vs 58 +/- 22 ml min-1).,The pharmacokinetics of perindopril in patients with liver cirrhosis. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576057/),[ml] / [min],26,8383,DB00790,Perindopril
,1576057,partial metabolic clearance,The partial metabolic clearance of perindopril to perindoprilat was much lower in the cirrhotics (26 +/- 12 ml min-1 vs 58 +/- 22 ml min-1).,The pharmacokinetics of perindopril in patients with liver cirrhosis. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576057/),[ml] / [min],58,8384,DB00790,Perindopril
,1576057,maximum inhibition,The maximum inhibition of plasma ACE activity measured in the cirrhotic patients (87.5 +/- 5.1%) was comparable with that previously reported with perindopril in patients with mild hepatic impairment as well as in patients with essential hypertension.,The pharmacokinetics of perindopril in patients with liver cirrhosis. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576057/),%,87.5,8385,DB00790,Perindopril
,8453964,maximal concentration,Administration for 1 month did not modify the time to peak perindoprilat concentration but significantly increased the mean maximal concentration: 10.2 versus 26.8 ng.,The effect of haemodialysis on the pharmacokinetics of perindoprilat after long-term perindopril. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453964/),ng,10.2,15067,DB00790,Perindopril
,8453964,maximal concentration,Administration for 1 month did not modify the time to peak perindoprilat concentration but significantly increased the mean maximal concentration: 10.2 versus 26.8 ng.,The effect of haemodialysis on the pharmacokinetics of perindoprilat after long-term perindopril. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453964/),ng,26.8,15068,DB00790,Perindopril
,8453964,accumulation ratio,The mean accumulation ratio was 3.5.,The effect of haemodialysis on the pharmacokinetics of perindoprilat after long-term perindopril. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453964/),,3.5,15069,DB00790,Perindopril
,8453964,clearance,Perindoprilat haemodialysis clearance was 62 ml.min-1 after the first administration and 72 ml.min-1 after 1 month.,The effect of haemodialysis on the pharmacokinetics of perindoprilat after long-term perindopril. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453964/),[ml] / [min],62,15070,DB00790,Perindopril
,8453964,clearance,Perindoprilat haemodialysis clearance was 62 ml.min-1 after the first administration and 72 ml.min-1 after 1 month.,The effect of haemodialysis on the pharmacokinetics of perindoprilat after long-term perindopril. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453964/),[ml] / [min],72,15071,DB00790,Perindopril
,1817672,Cross-reactivities,"Cross-reactivities for the glucuronide metabolites of P and PT are low (0.25 and 3.5%, respectively).",A new radioimmunoassay for the determination of the angiotensin-converting enzyme inhibitor perindopril and its active metabolite in plasma and urine: advantages of a lysine derivative as immunogen to improve the assay specificity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1817672/),%,0.25,30346,DB00790,Perindopril
,1817672,Cross-reactivities,"Cross-reactivities for the glucuronide metabolites of P and PT are low (0.25 and 3.5%, respectively).",A new radioimmunoassay for the determination of the angiotensin-converting enzyme inhibitor perindopril and its active metabolite in plasma and urine: advantages of a lysine derivative as immunogen to improve the assay specificity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1817672/),%,3.5,30347,DB00790,Perindopril
,1817672,limit of detection,"The theoretical limit of detection is 0.2 nM, the sensitivity attainable with random samples is about 0.5 nM.",A new radioimmunoassay for the determination of the angiotensin-converting enzyme inhibitor perindopril and its active metabolite in plasma and urine: advantages of a lysine derivative as immunogen to improve the assay specificity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1817672/),nM,0.2,30348,DB00790,Perindopril
,1817672,Recoveries,Recoveries of PT spiked to urine and plasma samples were 90-120%.,A new radioimmunoassay for the determination of the angiotensin-converting enzyme inhibitor perindopril and its active metabolite in plasma and urine: advantages of a lysine derivative as immunogen to improve the assay specificity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1817672/),%,90-120,30349,DB00790,Perindopril
,26794937,Cmax,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),[μg] / [ml],23.179,39047,DB00790,Perindopril
,26794937,tmax,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),h,0.729,39048,DB00790,Perindopril
,26794937,t1/2,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),h,1.429,39049,DB00790,Perindopril
,26794937,AUC0-t,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),[µgs] / [ml],26.998,39050,DB00790,Perindopril
,26794937,AUC0-inf,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),[µgs] / [ml],27.117,39051,DB00790,Perindopril
,26794937,Cmax,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),[μg] / [ml],1.834,39052,DB00790,Perindopril
,26794937,tmax,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),h,8.792,39053,DB00790,Perindopril
,26794937,t1/2,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),h,40.699,39054,DB00790,Perindopril
,26794937,AUC0-t,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),[µgs] / [ml],54.828,39055,DB00790,Perindopril
,26794937,AUC0-inf,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),[µgs] / [ml],77.113,39056,DB00790,Perindopril
,26794937,Cmax,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),[μg] / [ml],18.994,39057,DB00790,Perindopril
,26794937,tmax,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),h,3.417,39058,DB00790,Perindopril
,26794937,t1/2,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),h,16.626,39059,DB00790,Perindopril
,26794937,AUC0-t,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),[µgs] / [ml],385.829,39060,DB00790,Perindopril
,26794937,AUC0-inf,"The results of pharmacokinetic parameters for perindopril, perindoprilat and indapamide were found as Cmax = 23.179 µg/mL, tmax = 0.729 h, t1/2 = 1.429 h; AUC0-t = 26.998 µgs/mL, AUC0-inf = 27.117 µgs/mL; Cmax = 1.834 µg/mL, tmax = 8.792 h, t1/2 = 40.699 h; AUC0-t = 54.828 µgs/mL, AUC0-inf = 77.113 µgs/mL; Cmax = 18.994 µg/mL, tmax = 3.417 h, t1/2 = 16.626 h and AUC0-t = 385.829 µgs/mL, AUC0-inf = 410.728 µgs/mL respectively.",The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794937/),[µgs] / [ml],410.728,39061,DB00790,Perindopril
,2844467,Bioavailability,Bioavailability of S-9780 was increased in the elderly (35% +/- 17% compared with 19% +/- 7%; p less than 0.025) mainly because of increased conversion rather than absorption.,Influence of age on the pharmacokinetics and pharmacodynamics of perindopril. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2844467/),%,35,40242,DB00790,Perindopril
,2844467,Bioavailability,Bioavailability of S-9780 was increased in the elderly (35% +/- 17% compared with 19% +/- 7%; p less than 0.025) mainly because of increased conversion rather than absorption.,Influence of age on the pharmacokinetics and pharmacodynamics of perindopril. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2844467/),%,19,40243,DB00790,Perindopril
,2844467,Renal clearance,Renal clearance of S-9780 was lower in the elderly (67 +/- 31 ml/min compared with 110 +/- 39 ml/min; p less than 0.03).,Influence of age on the pharmacokinetics and pharmacodynamics of perindopril. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2844467/),[ml] / [min],67,40244,DB00790,Perindopril
,2844467,Renal clearance,Renal clearance of S-9780 was lower in the elderly (67 +/- 31 ml/min compared with 110 +/- 39 ml/min; p less than 0.03).,Influence of age on the pharmacokinetics and pharmacodynamics of perindopril. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2844467/),[ml] / [min],110,40245,DB00790,Perindopril
,28791494,Volume of distribution,"Volume of distribution, clearance and half-life median value (interquarti°range) for perindoprilat were 408.3 (360.4-456.8) L, 10.1 (4.9-17.0) L h-1 and 24.7 (19.4-62.7) h, respectively.",Adherence with perindopril therapy: a pilot study using therapeutic drug monitoring of perindoprilat and an evaluation of the clearance estimation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28791494/),l,408.3,42785,DB00790,Perindopril
,28791494,clearance,"Volume of distribution, clearance and half-life median value (interquarti°range) for perindoprilat were 408.3 (360.4-456.8) L, 10.1 (4.9-17.0) L h-1 and 24.7 (19.4-62.7) h, respectively.",Adherence with perindopril therapy: a pilot study using therapeutic drug monitoring of perindoprilat and an evaluation of the clearance estimation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28791494/),[l] / [h],10.1,42786,DB00790,Perindopril
,28791494,half-life,"Volume of distribution, clearance and half-life median value (interquarti°range) for perindoprilat were 408.3 (360.4-456.8) L, 10.1 (4.9-17.0) L h-1 and 24.7 (19.4-62.7) h, respectively.",Adherence with perindopril therapy: a pilot study using therapeutic drug monitoring of perindoprilat and an evaluation of the clearance estimation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28791494/),h,24.7,42787,DB00790,Perindopril
,15982858,apparent volume of distribution (V/F),"The kinetics of perindoprilat were dose dependent with the apparent volume of distribution (V/F) varying from 920 L at a dose of 3.1 mg of perindoprilat to 470 L at a dose of 12.3 mg, in normal volunteers.",The pharmacokinetics of perindoprilat in normal volunteers and patients: influence of age and disease state. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15982858/),l,920,95214,DB00790,Perindopril
,15982858,apparent volume of distribution (V/F),"The kinetics of perindoprilat were dose dependent with the apparent volume of distribution (V/F) varying from 920 L at a dose of 3.1 mg of perindoprilat to 470 L at a dose of 12.3 mg, in normal volunteers.",The pharmacokinetics of perindoprilat in normal volunteers and patients: influence of age and disease state. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15982858/),l,470,95215,DB00790,Perindopril
,15982858,Apparent unbound clearance (CLu/F),"Apparent unbound clearance (CLu/F) ranged from 59 to 110 L h(-1), showing no systematic trend with dose or from single to multiple dosing.",The pharmacokinetics of perindoprilat in normal volunteers and patients: influence of age and disease state. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15982858/),[l] / [h],59 to 110,95216,DB00790,Perindopril
,33706186,extraction recovery,"The average extraction recovery of perindopril, perindoprilat and indapamide samples at low, medium, and high concentration levels were between 85.9% and 93.6%, respectively.","Simultaneous determination of indapamide, perindopril and its active metabolite perindoprilat in human plasma using UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33706186/),%,85.9,97193,DB00790,Perindopril
,33706186,extraction recovery,"The average extraction recovery of perindopril, perindoprilat and indapamide samples at low, medium, and high concentration levels were between 85.9% and 93.6%, respectively.","Simultaneous determination of indapamide, perindopril and its active metabolite perindoprilat in human plasma using UPLC-MS/MS method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33706186/),%,93.6,97194,DB00790,Perindopril
,2311339,partial metabolic clearance,"Food significantly decreased the relative availability of perindoprilat by 35% +/- 42%, the fractional urinary excretion of perindoprilat from 19% +/- 7% to 13% +/- 4% (p less than 0.05), and the partial metabolic clearance of perindopril to perindoprilat from 102 +/- 57 ml.min-1 to 72 +/- 32 ml.min-1 (p less than 0.05).",Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311339/),[ml] / [min],102,97970,DB00790,Perindopril
,2311339,partial metabolic clearance,"Food significantly decreased the relative availability of perindoprilat by 35% +/- 42%, the fractional urinary excretion of perindoprilat from 19% +/- 7% to 13% +/- 4% (p less than 0.05), and the partial metabolic clearance of perindopril to perindoprilat from 102 +/- 57 ml.min-1 to 72 +/- 32 ml.min-1 (p less than 0.05).",Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311339/),[ml] / [min],72,97971,DB00790,Perindopril
over,2505711,terminal half life,"After intravenous administration, perindoprilat concentrations show multiexponential decay with a terminal half life of over 30 hours associated with sustained inhibition of ACE.",Pharmacokinetics of perindopril: therapeutic consequences. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2505711/),h,30,98013,DB00790,Perindopril
,9402466,T:P,ACE inhibitors with appropriate pharmacokinetics such as perindopril can control blood pressure when titrated at peak provided a dose is used (4 or 8 mg) that is known to have a T:P close to 1.0.,Adequate blood pressure control: perception and reality. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402466/),,1.0,98024,DB00790,Perindopril
,1657092,area under the serum concentration-time curve,"The mean area under the serum concentration-time curve of the active metabolite perindoprilat increased from 93 ng ml-1 h in subjects with normal renal function to 1106 ng ml-1 in patients with severe renal failure, whereas its half-life varied from 5.0 to 27.4 h.",Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1657092/),[h·ng] / [ml],93,122949,DB00790,Perindopril
,1657092,area under the serum concentration-time curve,"The mean area under the serum concentration-time curve of the active metabolite perindoprilat increased from 93 ng ml-1 h in subjects with normal renal function to 1106 ng ml-1 in patients with severe renal failure, whereas its half-life varied from 5.0 to 27.4 h.",Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1657092/),[ng] / [ml],1106,122950,DB00790,Perindopril
,1657092,half-life,"The mean area under the serum concentration-time curve of the active metabolite perindoprilat increased from 93 ng ml-1 h in subjects with normal renal function to 1106 ng ml-1 in patients with severe renal failure, whereas its half-life varied from 5.0 to 27.4 h.",Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1657092/),h,5.0 to 27.4,122951,DB00790,Perindopril
,1657092,area under the curve,"5 In the same subjects, the mean area under the curve of perindoprilat glucuronide increased from 78 to 513 ng ml-1 h, while its half-life varied from 1.8 h to 7.7 h.",Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1657092/),[h·ng] / [ml],78,122952,DB00790,Perindopril
,1657092,half-life,"5 In the same subjects, the mean area under the curve of perindoprilat glucuronide increased from 78 to 513 ng ml-1 h, while its half-life varied from 1.8 h to 7.7 h.",Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1657092/),h,1.8,122953,DB00790,Perindopril
,1657092,half-life,"5 In the same subjects, the mean area under the curve of perindoprilat glucuronide increased from 78 to 513 ng ml-1 h, while its half-life varied from 1.8 h to 7.7 h.",Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1657092/),h,7.7,122954,DB00790,Perindopril
,1657092,half-life of inhibition,The half-life of inhibition varied from 12.1 h to 100.4 h.,Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1657092/),h,12.1,122955,DB00790,Perindopril
,1657092,half-life of inhibition,The half-life of inhibition varied from 12.1 h to 100.4 h.,Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1657092/),h,100.4,122956,DB00790,Perindopril
,2175584,keo,"We obtained keo = 0.60 +/- 0.30 h-1 (mean +/- s.d.), Emax = 90 +/- 10 p. 100, EC50 = 1.30 +/- 0.95 ng/ml.(ABSTRACT TRUNCATED AT 250 WORDS)",[Modeling of the relation between plasma concentration of the active metabolite of perindopril and inhibition of the activity of plasma converting enzyme in healthy volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2175584/),1/[h],0.60,124670,DB00790,Perindopril
,2175584,Emax,"We obtained keo = 0.60 +/- 0.30 h-1 (mean +/- s.d.), Emax = 90 +/- 10 p. 100, EC50 = 1.30 +/- 0.95 ng/ml.(ABSTRACT TRUNCATED AT 250 WORDS)",[Modeling of the relation between plasma concentration of the active metabolite of perindopril and inhibition of the activity of plasma converting enzyme in healthy volunteers]. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2175584/),100·p,90,124671,DB00790,Perindopril
,2175584,EC50,"We obtained keo = 0.60 +/- 0.30 h-1 (mean +/- s.d.), Emax = 90 +/- 10 p. 100, EC50 = 1.30 +/- 0.95 ng/ml.(ABSTRACT TRUNCATED AT 250 WORDS)",[Modeling of the relation between plasma concentration of the active metabolite of perindopril and inhibition of the activity of plasma converting enzyme in healthy volunteers]. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2175584/),[ng] / [ml],1.30,124672,DB00790,Perindopril
over,2605799,terminal half-life,"After intravenous administration, perindoprilat concentrations show multiexponential decay with a terminal half-life of over 30 hours, associated with sustained inhibition of ACE.",Pharmacokinetics of perindopril: therapeutic consequences. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2605799/),h,30,140393,DB00790,Perindopril
,8440763,serum area under the curve for 24 hours,"Chronic treatment with perindopril produced no significant effect on mean (+/- standard deviation) digoxin serum area under the curve for 24 hours (17.9 +/- 7.4 versus 16.3 +/- 4.4 ng/mL.h), peak digoxin concentration (1.3 +/- 0.54 versus 1.2 +/- 0.36 ng/mL), time to peak concentration (3 versus 4 hours), and apparent oral clearance of digoxin (237.7 +/- 109.6 versus 237.4 +/- 79.5 mL/min).",Digoxin pharmacokinetics and perindopril in heart failure patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8440763/),[ng] / [h·ml],17.9,144851,DB00790,Perindopril
,8440763,serum area under the curve for 24 hours,"Chronic treatment with perindopril produced no significant effect on mean (+/- standard deviation) digoxin serum area under the curve for 24 hours (17.9 +/- 7.4 versus 16.3 +/- 4.4 ng/mL.h), peak digoxin concentration (1.3 +/- 0.54 versus 1.2 +/- 0.36 ng/mL), time to peak concentration (3 versus 4 hours), and apparent oral clearance of digoxin (237.7 +/- 109.6 versus 237.4 +/- 79.5 mL/min).",Digoxin pharmacokinetics and perindopril in heart failure patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8440763/),[ng] / [h·ml],16.3,144852,DB00790,Perindopril
,8440763,peak digoxin concentration,"Chronic treatment with perindopril produced no significant effect on mean (+/- standard deviation) digoxin serum area under the curve for 24 hours (17.9 +/- 7.4 versus 16.3 +/- 4.4 ng/mL.h), peak digoxin concentration (1.3 +/- 0.54 versus 1.2 +/- 0.36 ng/mL), time to peak concentration (3 versus 4 hours), and apparent oral clearance of digoxin (237.7 +/- 109.6 versus 237.4 +/- 79.5 mL/min).",Digoxin pharmacokinetics and perindopril in heart failure patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8440763/),[ng] / [ml],1.3,144853,DB00790,Perindopril
,8440763,peak digoxin concentration,"Chronic treatment with perindopril produced no significant effect on mean (+/- standard deviation) digoxin serum area under the curve for 24 hours (17.9 +/- 7.4 versus 16.3 +/- 4.4 ng/mL.h), peak digoxin concentration (1.3 +/- 0.54 versus 1.2 +/- 0.36 ng/mL), time to peak concentration (3 versus 4 hours), and apparent oral clearance of digoxin (237.7 +/- 109.6 versus 237.4 +/- 79.5 mL/min).",Digoxin pharmacokinetics and perindopril in heart failure patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8440763/),[ng] / [ml],1.2,144854,DB00790,Perindopril
,8440763,time to peak concentration,"Chronic treatment with perindopril produced no significant effect on mean (+/- standard deviation) digoxin serum area under the curve for 24 hours (17.9 +/- 7.4 versus 16.3 +/- 4.4 ng/mL.h), peak digoxin concentration (1.3 +/- 0.54 versus 1.2 +/- 0.36 ng/mL), time to peak concentration (3 versus 4 hours), and apparent oral clearance of digoxin (237.7 +/- 109.6 versus 237.4 +/- 79.5 mL/min).",Digoxin pharmacokinetics and perindopril in heart failure patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8440763/),h,3,144855,DB00790,Perindopril
,8440763,time to peak concentration,"Chronic treatment with perindopril produced no significant effect on mean (+/- standard deviation) digoxin serum area under the curve for 24 hours (17.9 +/- 7.4 versus 16.3 +/- 4.4 ng/mL.h), peak digoxin concentration (1.3 +/- 0.54 versus 1.2 +/- 0.36 ng/mL), time to peak concentration (3 versus 4 hours), and apparent oral clearance of digoxin (237.7 +/- 109.6 versus 237.4 +/- 79.5 mL/min).",Digoxin pharmacokinetics and perindopril in heart failure patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8440763/),h,4,144856,DB00790,Perindopril
,8440763,apparent oral clearance,"Chronic treatment with perindopril produced no significant effect on mean (+/- standard deviation) digoxin serum area under the curve for 24 hours (17.9 +/- 7.4 versus 16.3 +/- 4.4 ng/mL.h), peak digoxin concentration (1.3 +/- 0.54 versus 1.2 +/- 0.36 ng/mL), time to peak concentration (3 versus 4 hours), and apparent oral clearance of digoxin (237.7 +/- 109.6 versus 237.4 +/- 79.5 mL/min).",Digoxin pharmacokinetics and perindopril in heart failure patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8440763/),[ml] / [min],237.7,144857,DB00790,Perindopril
,8440763,apparent oral clearance,"Chronic treatment with perindopril produced no significant effect on mean (+/- standard deviation) digoxin serum area under the curve for 24 hours (17.9 +/- 7.4 versus 16.3 +/- 4.4 ng/mL.h), peak digoxin concentration (1.3 +/- 0.54 versus 1.2 +/- 0.36 ng/mL), time to peak concentration (3 versus 4 hours), and apparent oral clearance of digoxin (237.7 +/- 109.6 versus 237.4 +/- 79.5 mL/min).",Digoxin pharmacokinetics and perindopril in heart failure patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8440763/),[ml] / [min],237.4,144858,DB00790,Perindopril
,25279159,MRTinf,"However, in the repeated co-administration for a week at a 2-h interval, which was more than perindopril MRTinf in the control treatment (1.5±0.1 h), the initial co-administration showed no differences in the pharmacokinetics between the combination and control treatments.","Effects of Chungsinoryungsan, a polyherbal complex, on the pharmacokinetic profiles of perindopril in rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25279159/),h,1.5,145189,DB00790,Perindopril
,7640141,time to maximum concentration (tmax),"2. The time to maximum concentration (tmax) for perindopril was shorter for the Chinese group after the 4 mg dose (median 0.5, range 0.5-1.5 h vs median 1.0, 0.5-1.5 h P < 0.05) and also tended to be shorter after the weight-adjusted dose (median 0.5, range 0.5-1.0 h vs median 1.0, range 0.5-3.0 h).",Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7640141/),h,0.5,165865,DB00790,Perindopril
,7640141,time to maximum concentration (tmax),"2. The time to maximum concentration (tmax) for perindopril was shorter for the Chinese group after the 4 mg dose (median 0.5, range 0.5-1.5 h vs median 1.0, 0.5-1.5 h P < 0.05) and also tended to be shorter after the weight-adjusted dose (median 0.5, range 0.5-1.0 h vs median 1.0, range 0.5-3.0 h).",Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7640141/),h,1.0,165866,DB00790,Perindopril
,7640141,time to maximum concentration (tmax),"2. The time to maximum concentration (tmax) for perindopril was shorter for the Chinese group after the 4 mg dose (median 0.5, range 0.5-1.5 h vs median 1.0, 0.5-1.5 h P < 0.05) and also tended to be shorter after the weight-adjusted dose (median 0.5, range 0.5-1.0 h vs median 1.0, range 0.5-3.0 h).",Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7640141/),h,0.5,165867,DB00790,Perindopril
,7640141,time to maximum concentration (tmax),"2. The time to maximum concentration (tmax) for perindopril was shorter for the Chinese group after the 4 mg dose (median 0.5, range 0.5-1.5 h vs median 1.0, 0.5-1.5 h P < 0.05) and also tended to be shorter after the weight-adjusted dose (median 0.5, range 0.5-1.0 h vs median 1.0, range 0.5-3.0 h).",Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7640141/),h,1.0,165868,DB00790,Perindopril
,1311597,serum accumulation ratio,After chronic administration the serum accumulation ratio was 1.81 in patients with mild renal failure and 5.35 in patients with severe renal failure.,The pharmacokinetics of perindopril and its effects on serum angiotensin converting enzyme activity in hypertensive patients with chronic renal failure. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1311597/),,1.81,179189,DB00790,Perindopril
,1311597,serum accumulation ratio,After chronic administration the serum accumulation ratio was 1.81 in patients with mild renal failure and 5.35 in patients with severe renal failure.,The pharmacokinetics of perindopril and its effects on serum angiotensin converting enzyme activity in hypertensive patients with chronic renal failure. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1311597/),,5.35,179190,DB00790,Perindopril
,1311597,IC50,Values of IC50 were 1.11 +/- 0.07 micrograms I-1 (mean +/- s.d.) in patients with severe renal failure and 1.81 +/- 0.20 micrograms l-1 in patients with moderate renal failure.,The pharmacokinetics of perindopril and its effects on serum angiotensin converting enzyme activity in hypertensive patients with chronic renal failure. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1311597/),[μg] / [i],1.11,179191,DB00790,Perindopril
,1311597,IC50,Values of IC50 were 1.11 +/- 0.07 micrograms I-1 (mean +/- s.d.) in patients with severe renal failure and 1.81 +/- 0.20 micrograms l-1 in patients with moderate renal failure.,The pharmacokinetics of perindopril and its effects on serum angiotensin converting enzyme activity in hypertensive patients with chronic renal failure. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1311597/),[μg] / [l],1.81,179192,DB00790,Perindopril
,31845865,total chromatographic run time,"The total chromatographic run time was 4 minutes with retention time for perindopril and perindopril-d4 of ~ 1.86 minutes, whereas perindoprilat and perindoprilat-d4 was ~ 1.79 minutes.",A UPLC-MS/MS method for quantification of perindopril and perindoprilat and applied in a bioequivalence study for their pharmacokinetic parameter measurement . ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31845865/),min,4,189181,DB00790,Perindopril
,31845865,retention time,"The total chromatographic run time was 4 minutes with retention time for perindopril and perindopril-d4 of ~ 1.86 minutes, whereas perindoprilat and perindoprilat-d4 was ~ 1.79 minutes.",A UPLC-MS/MS method for quantification of perindopril and perindoprilat and applied in a bioequivalence study for their pharmacokinetic parameter measurement . ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31845865/),min,1.86,189182,DB00790,Perindopril
,31845865,retention time,"The total chromatographic run time was 4 minutes with retention time for perindopril and perindopril-d4 of ~ 1.86 minutes, whereas perindoprilat and perindoprilat-d4 was ~ 1.79 minutes.",A UPLC-MS/MS method for quantification of perindopril and perindoprilat and applied in a bioequivalence study for their pharmacokinetic parameter measurement . ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31845865/),min,1.79,189183,DB00790,Perindopril
,2441162,terminal half-life (t1/2),The pharmacokinetics of S-9780 fitted a three-compartment model with a terminal half-life (t1/2) of 31 h.,"Effects of intravenous S-9780, an angiotensin-converting enzyme inhibitor, in normotensive subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2441162/),h,31,204335,DB00790,Perindopril
,33314205,flow rate,"Ammonium acetate and methanol, pumped at a flow rate of 0.3 ml/min, were used as a mobile phase.","Determination of amlodipine, indapamide and perindopril in human plasma by a novel LC-MS/MS method: Application to a bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33314205/),[ml] / [min],0.3,212489,DB00790,Perindopril
,2351367,oral bioavailability,Perindopril is rapidly absorbed with an oral bioavailability of 95% and is mainly eliminated by metabolic processes.,Pharmacokinetics of perindopril and its metabolites in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2351367/),%,95,247206,DB00790,Perindopril
,12808303,clearance (CL(HD)),"Values of haemodialysis clearance (CL(HD)) and extraction ratio (ER) were 51.5+/-30.2 ml/min and 0.35+/-0.21 for quinaprilat and 108.1+/-5.9 ml/min and 0.75+/-0.04 for perindoprilat, respectively.",Elimination kinetics of quinaprilat and perindoprilat in hypertensive patients with renal failure on haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12808303/),[ml] / [min],51.5,253053,DB00790,Perindopril
,12808303,clearance (CL(HD)),"Values of haemodialysis clearance (CL(HD)) and extraction ratio (ER) were 51.5+/-30.2 ml/min and 0.35+/-0.21 for quinaprilat and 108.1+/-5.9 ml/min and 0.75+/-0.04 for perindoprilat, respectively.",Elimination kinetics of quinaprilat and perindoprilat in hypertensive patients with renal failure on haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12808303/),[ml] / [min],108.1,253054,DB00790,Perindopril
,12808303,extraction ratio (ER),"Values of haemodialysis clearance (CL(HD)) and extraction ratio (ER) were 51.5+/-30.2 ml/min and 0.35+/-0.21 for quinaprilat and 108.1+/-5.9 ml/min and 0.75+/-0.04 for perindoprilat, respectively.",Elimination kinetics of quinaprilat and perindoprilat in hypertensive patients with renal failure on haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12808303/),,0.35,253055,DB00790,Perindopril
,12808303,extraction ratio (ER),"Values of haemodialysis clearance (CL(HD)) and extraction ratio (ER) were 51.5+/-30.2 ml/min and 0.35+/-0.21 for quinaprilat and 108.1+/-5.9 ml/min and 0.75+/-0.04 for perindoprilat, respectively.",Elimination kinetics of quinaprilat and perindoprilat in hypertensive patients with renal failure on haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12808303/),,0.75,253056,DB00790,Perindopril
,12808303,terminal elimination half-lives,"The terminal elimination half-lives of quinaprilat and perindoprilat were 60.7+/-2.1 and 79.9+/-14.0 h, respectively.",Elimination kinetics of quinaprilat and perindoprilat in hypertensive patients with renal failure on haemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12808303/),h,60.7,253057,DB00790,Perindopril
,12808303,terminal elimination half-lives,"The terminal elimination half-lives of quinaprilat and perindoprilat were 60.7+/-2.1 and 79.9+/-14.0 h, respectively.",Elimination kinetics of quinaprilat and perindoprilat in hypertensive patients with renal failure on haemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12808303/),h,79.9,253058,DB00790,Perindopril
,1279299,elimination t1/2,Perindopril peak levels were achieved in less than or equal to 2 h after dosing with an elimination t1/2 of 1-2 h.,Single-dose and steady-state pharmacokinetics and pharmacodynamics of perindopril in hypertensive subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1279299/),h,1-2,260239,DB00790,Perindopril
,1279299,elimination t1/2,"Peak levels of perindoprilat were achieved more slowly, reaching a maximum level 5-8 h after dosing, and had an elimination t1/2 of 40 h.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of perindopril in hypertensive subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1279299/),h,40,260240,DB00790,Perindopril
,1279299,elimination t1/2,"Levels of the perindopril glucuronide peaked approximately 0.5 h later than perindopril, with an elimination t1/2 of approximately 2 h.",Single-dose and steady-state pharmacokinetics and pharmacodynamics of perindopril in hypertensive subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1279299/),h,2,260241,DB00790,Perindopril
,7614778,bioavailability,"Theophylline has higher bioavailability in patients with oedema, with a significantly higher Cmax in patients with hepatic cirrhosis and CHF than in healthy volunteers (29 and 22%, respectively).",Pharmacokinetic changes in patients with oedema. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614778/),%,29,269967,DB00790,Perindopril
,7614778,bioavailability,"Theophylline has higher bioavailability in patients with oedema, with a significantly higher Cmax in patients with hepatic cirrhosis and CHF than in healthy volunteers (29 and 22%, respectively).",Pharmacokinetic changes in patients with oedema. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614778/),%,22,269968,DB00790,Perindopril
